Last reviewed · How we verify

Stefania La Grutta, MD — Portfolio Competitive Intelligence Brief

Stefania La Grutta, MD pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Nasal Beclomethasone Dipropionate Nasal Beclomethasone Dipropionate marketed Intranasal corticosteroid Glucocorticoid receptor Immunology / Allergy

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Association Asthma, Bulgaria · 1 shared drug class
  2. AstraZeneca · 1 shared drug class
  3. Beijing Tongren Hospital · 1 shared drug class
  4. Children's Hospital of Philadelphia · 1 shared drug class
  5. GlaxoSmithKline · 1 shared drug class
  6. Glenmark Specialty S.A. · 1 shared drug class
  7. McGill University Health Centre/Research Institute of the McGill University Health Centre · 1 shared drug class
  8. National University of Malaysia · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Stefania La Grutta, MD:

Cite this brief

Drug Landscape (2026). Stefania La Grutta, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/stefania-la-grutta-md. Accessed 2026-05-16.

Related